



## **JAGSONPAL PHARMACEUTICALS LIMITED**

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)  
Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24  
E-mail: admin@jagsonpal.com

JPL/SEC/RESU-NOT

Date : November 12th, 2011

The National Stock Exchange of India Limited  
Kind Attn. Mr. Hari K. - Vice President  
Exchange Plaza, Bandra-Kurla Complex  
Bandra E), Mumbai - 400 051.  
**FAX 022-26598237-38**

The Bombay Stock Exchange Limited  
Pherozebhoj Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001  
**FAX 022-22723121, 22722037, 22723719, 22722041**

### **SUB: UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30.09.2011 & Limited Review.**

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith unaudited financial results (provisional) for the quarter ended 30th September, 2011 and Limited Review.

Thanking you.

Yours faithfully,  
for **JAGSONPAL PHARMACEUTICALS LIMITED**

**(S.K. MATA)**  
**COMPLIANCE OFFICER CUM COMPANY SECRETARY**



Encl. : As above.



## JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 30.09.2011

Rs. in lacs

Particulars	Quarter ended 30.09.2011 Unaudited	Quarter Ended 30.09.2010 Unaudited	Six Month ended 30.09.2011 Unaudited	Six Month Ended 30.09.2010 Unaudited	12 Months Ended 31.03.2011 Audited
1a Net sales/Income from Operations	4765.49	4583.54	8845.53	8700.58	16095.50
1b Other Operating Income					
Total	4765.49	4583.54	8845.53	8700.58	16095.50
2 Expenditure					
a. (Inc./Dec. in Stock in trade & work in progress	-368.32	647.94	-551.53	796.49	192.46
b. Consumption of Raw Materials	2367.77	1173.69	4449.21	3126.52	7379.61
c. Purchase of traded goods	290.03	433.40	436.28	566.71	727.95
d. Employees Cost	927.74	901.38	1778.23	1586.19	3222.48
e. Depreciation	62.15	58.09	120.08	115.11	220.09
f. Other Expenditure	1061.50	881.43	1907.20	1587.60	3119.94
g. Total	4340.87	4095.93	8139.47	7778.62	14862.53
3 Profit from Operations before Other Income, Interest and Exceptional items (1-2)	424.62	487.61	706.06	921.96	1232.97
4 Other Income	6.01	0.00	6.01	0.00	26.02
5 Profit before Interest and Exceptional items (3+4)	430.63	487.61	712.07	921.96	1258.99
6 Interest	103.62	110.61	179.65	186.33	332.18
7 Profit after Interest but before Exceptional Items (5-6)	327.01	377.00	532.42	735.63	926.81
8 Exceptional Items					
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	327.01	377.00	532.42	735.63	926.81
10 Tax expense	73.00	100.00	113.00	135.00	208.85
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	254.01	277.00	419.42	600.63	717.96
12 Extraordinary Items (net of tax expense)					
13 Net Profit(+)/Loss(-) for the period(11-12)	254.01	277.00	419.42	600.63	717.96
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of previous Accounting year					6615.03
16 Earnings Per Share (EPS)					
a. Basic & diluted EPS before extraordinary items for the period.	0.97	1.06	1.60	2.29	2.74
b. Basic & diluted EPS after extraordinary items for the period.	0.97	1.06	1.60	2.29	2.74
17 Public shareholding :					
- Number of shares	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding					
A Pledged / encumbered :					
- Number of shares					
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
B Non - encumbered					
- Number of shares	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%

### Notes

- The Financial Results for the Quarter ended 30.09.2011 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 12-11-2011
- No complaints were pending at the beginning/end of the quarter ended 30.09.2011. However 17 requests for change of address/dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director

Place : New Delhi  
Date : 12.11.2011

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone:0091-95129-2275952, 2275953  
Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar)-263153 Uttara Khand

**TO WHOM IT MAY CONCERN**

We have reviewed the accompanying statement of un-audited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.09.2011. This statement is the responsibility of the Company's management and has been approved by the Audit Committee and Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial statement issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not excess an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : New Delhi  
Date : 12/11/2011

for P. P. THUKRAL & CO.,  
Chartered Accountants

  
SURESH SETHI  
PARTNER

F.R. No. 000632 N  
Membership no. 89318